ROCKVILLE, Md. , Nov. 25, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conference:
Piper Sandler 37 th Annual Healthcare Conference
Fireside Chat: Tuesday, December 2 at 8:30 a.m. ET
Location: New York, NY
A live webcast of the fireside chat can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com . An archived replay of the webcast will be available for approximately 30 days following the event.
ABOUT REGENXBIO Inc.
REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit WWW.REGENXBIO.COM .
Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com
Investors:
George E. MacDougall
Investor Relations
IR@regenxbio.com
View original content to download multimedia: https://www.prnewswire.com/news-releases/regenxbio-to-participate-in-upcoming-investor-conference-302625302.html
SOURCE REGENXBIO Inc.
/Cybersecurity%20by%20AIBooth%20via%20Shutterstock.jpg)